Canaccord Genuity Reiterates a 'Buy' on Solazyme (SZYM); Encouraged by Management’s Execution
Tweet
Share
E-mailGet Alerts SZYM Hot Sheet
Price: $2.15 --0%
Rating Summary:
5 Buy, 6 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
5 Buy, 6 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Solazyme (NASDAQ: SZYM) price target of $19.00.
Analyst, John Quealy, said, "We come away encouraged by management’s execution on milestones thus far. Algenist continues to gain traction (and experience) and drive near-term product revenues, while the Street looks for the formalization of the Bunge JV this year and related plant groundbreaking (’13) as key events signaling the progression of planned capacity additions."
"SZYM reported Q4/11 revenue/GAAP EPS of $14.9M/$(0.26) vs. our modeled $15.0M/$(0.16) and consensus at $15.1M/$(0.16). We note that heavier than expected R&D expense largely accounted for the EPS variance (~$0.09 headwind). We continue to find financial results to be less meaningful than progress vs. key milestones at this point."
For an analyst ratings summary and ratings history on Solazyme click here. For more ratings news on Solazyme click here.
Shares of Solazyme closed at $11.87 yesterday.
Analyst, John Quealy, said, "We come away encouraged by management’s execution on milestones thus far. Algenist continues to gain traction (and experience) and drive near-term product revenues, while the Street looks for the formalization of the Bunge JV this year and related plant groundbreaking (’13) as key events signaling the progression of planned capacity additions."
"SZYM reported Q4/11 revenue/GAAP EPS of $14.9M/$(0.26) vs. our modeled $15.0M/$(0.16) and consensus at $15.1M/$(0.16). We note that heavier than expected R&D expense largely accounted for the EPS variance (~$0.09 headwind). We continue to find financial results to be less meaningful than progress vs. key milestones at this point."
For an analyst ratings summary and ratings history on Solazyme click here. For more ratings news on Solazyme click here.
Shares of Solazyme closed at $11.87 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- Freedom Broker Upgrades Serve Robotics (SERV) to Buy
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS ViewRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
